New experimental drug CTX-8371 enters first human tests for tough cancers
NCT ID NCT06150664
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 participants will receive the drug by IV every two weeks. Because this is a first-in-human trial, it is too early to know if the drug will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Email: •••••@•••••
-
D&H Cancer Research Center
WITHDRAWNMargate, Florida, 33063, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Florida Cancer Specialists - Lake Nona
RECRUITINGOrlando, Florida, 32827, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34236, United States
Contact
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Summit Cancer Center
RECRUITINGSpokane, Washington, 99208, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Email: •••••@•••••
-
University Cancer & Blood Center
RECRUITINGAthens, Georgia, 30607, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX-8371 (an experimental drug given by IV infusion every two weeks)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 85 participants, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects, and it will take years before it might become available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.